[Quality assurance in patient addiction treated with drug substitution].
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects; D015897:Comorbidity; D004346:Drug Information Services; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004502:Education, Medical, Continuing; D006526:Hepatitis C / Q000150:complications / Q000451:nursing* / Q000534:rehabilitation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008691:Methadone / Q000008:administration & dosage* / Q000009:adverse effects; D019212:Multimedia; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009293:Opioid-Related Disorders / Q000150:complications / Q000451:nursing* / Q000534:rehabilitation; D011092:Polyethylene Glycols; D011785:Quality Assurance, Health Care; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009292:Narcotic Antagonists; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D002047:Buprenorphine; D012254:Ribavirin; C417083:peginterferon alfa-2b; D008691:Methadone